Riskpilot← Back to searchSign inGet full accessAktiebolaget Serlexa
ABActiveOrg 5563047439Research and experimental development on natural sciences and engineering · NACE 7210Est. 19870 employees
Revenue 2024
SEK 41K
-32% vs 2023
EBITDA margin
167.4%
-27% vs 2023
Equity ratio
77.7%
Financial strength
Net profit 2024
SEK 18K
-22% vs 2023
| Revenue | SEK 41K | -32% |
| EBITDA | SEK 69K | -27% |
| Net profit | SEK 18K | -22% |
| Total assets | SEK 3,9M | -2% |
| Equity | SEK 3M | +1% |
| Employees | 0 | — |
Legal name
Aktiebolaget Serlexa
Org number
5563047439
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 september 1987
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall driva konsultverksamhet samt handel och agenturverksamhet inom det medicinska området, köp och försäljning av värdehandlingar, frimärken och andra samlarobjekt, förvaltning av fastigheter, läkarverksamhet jämte därmed förenlig.
Address
Phone
+4640457079
Email
goran.samsioe@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 51 | 56 | 51 | 60 | 41 |
| Staff expenses | — | — | −42 | −53 | −41 |
| EBITDA | 10 | 13 | 95 | 94 | 69 |
| Depreciation & amort. | −48 | −48 | −48 | −48 | −48 |
| EBIT | −38 | −35 | 47 | 46 | 21 |
| Net financials | — | −40 | −71 | −16 | 2 |
| Profit before tax | 7 | 0 | 106 | 29 | 23 |
| Tax | −2 | −1 | −24 | −6 | −4 |
| Net profit | 5 | −1 | 82 | 23 | 18 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 149 | 4 011 | 4 074 | 4 013 | 3 927 |
| Equity | 2 927 | 2 926 | 3 008 | 3 031 | 3 050 |
| Long-term debt | 778 | 682 | 682 | 538 | 510 |
| Short-term debt | 240 | 274 | 384 | 444 | 367 |
| Total debt | 1 018 | 956 | 1 066 | 982 | 877 |
EBITDA margin
167.4%
This company
15.8%
Market median
+959% vs market
20202024
Equity ratio
77.7%
This company
38.2%
Market median
+103% vs market
20202024
Return on equity
0.6%
This company
18.4%
Market median
-97% vs market
20202024
Net profit margin
44.4%
This company
8.1%
Market median
+448% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
0.29×
This company
0.62×
Market median
+53% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2026 | |
| Deputy Board Member | 2026 | |
| Former (3) | ||
| Deputy Board Member | 2022 – 2026 | |
| Deputy Board Member | 2026 – 2026 | |
| Board of Directors | 2022 – 2026 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Aktiebolaget Serlexa also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ann Marie Louice Samsioe | Deputy Board Member | 0 companies |
| Inger Birgitta Rembeck | Board of Directors | 0 companies |
| Staffan Arne Donald Olsson | Deputy Board Member | 0 companies |
| Anna-Clara Rönner | Deputy Board Member | 0 companies |
| Nils Göran Samsioe | Board of Directors | 0 companies |